U.S. Meibomian Gland Dysfunction Market, By Drug Type (Cyclosporine, Omega-3 supplements, Antibacterial eye drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), HY02 - Minocycline), By Route of Administration (Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Meibomian gland dysfunction (MGD) is a term used to describe a group of disorders, both congenital and acquired. Disruption of meibomian gland function negatively impacts both the quality and quantity of meibum secreted, which in turn affects ocular surface health through changes in tear film composition. Increased tear evaporation, hyperosmolarity, inflammation, and ocular surface damage can subsequently occur and cause discomfort, visual disruption, and sensation of dry eyes. The meibomian gland dysfunction market is expected to develop due to the rising demand for coronavirus meibomian gland dysfunctions. Governments and medical regulators accelerated meibomian gland dysfunction development due to the epidemic's severity, even though normal meibomian gland dysfunction development needed years to complete the necessary testing. Factors such as the growing prevalence of infectious diseases, innovative technology in meibomian gland dysfunction development, increased funding from government and international organizations, and the increasing government focus on immunization programs are boosting the market's growth.
Market Dynamics
The key market players are focusing on the adoption of growth and organic strategies such as the launch of new drugs, which is attributed to the growth of the U.S. meibomian gland dysfunctions market. For instance, in January 2021, Kala Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company., launched EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional United States pharmaceutical distribution centers. Patients with a prescription can access EYSUVIS through their local retail pharmacies or home delivery.
Key features of the study:
This report provides an in-depth analysis of the U.S. meibomian gland dysfunction market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. meibomian gland dysfunction market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, and Akorn, inc. AFT Pharmaceuticals, Alcon Inc., Horus Pharma, Mitotech, Novaliq GmbH, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Ltd, and VISUfarma.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
U.S. meibomian gland dysfunction market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. meibomian gland dysfunction market
Detailed Segmentation:
U.S. Meibomian Gland Dysfunctions Market, By Drug Type:
Cyclosporine
Omega-3 supplements
Antibacterial Eye Drops
Steroids
AZR MD 001
TP 03
NOV03 (Novatears)
HY02 – Minocycline
U.S. Meibomian Gland Dysfunctions Market, By Route of Administration:
Oral
Topical
U.S. Meibomian Gland Dysfunction Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Pfizer, Inc.
AbbVie Inc.
Johnson and Johnson Vision Care Inc.
Bausch Health Companies Inc.
Novartis AG
Santen Pharmaceutical Co., Ltd.
I-MED Pharma Inc.
OASIS Medical
Sentiss Pharma Pvt. Ltd.
RegeneRx
Akorn, Inc.
AFT Pharmaceuticals
Alcon Inc.
Horus Pharma
Mitotech
Novaliq GmbH
Otsuka Pharmaceutical Co. Ltd
Prestige Consumer Healthcare
Santen Pharmaceutical Co. Ltd
Sun Pharmaceutical Industries Ltd
VISUfarma.
1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Key Developments
Epidemiology
Merger, Acquisition, and Collaboration
Regulatory Scenario
PEST Analysis
4. U.S. Meibomian Gland Dysfunction Market– COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. U.S. Meibomian Gland Dysfunction Market, By Drug Type, 2018–2030 (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Cyclosporine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Omega-3 supplements
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Omega-3 supplements
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Antibacterial Eye Drops
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Steroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
AZR MD 001
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
TP 03
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
NOV03 (Novatears)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
HY02–Minocycline
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
6. U.S. Meibomian Gland Dysfunction Market, By Route of Administration, 2018–2030 (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Topical
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
7. U.S. Meibomian Gland Dysfunction Market, By Distribution Channel, 2018–2030 (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)